{"id":17805,"date":"2026-07-07T10:42:05","date_gmt":"2026-07-07T10:42:05","guid":{"rendered":"https:\/\/www.eyecliniclondon.com\/blog\/?p=17805"},"modified":"2026-07-07T10:42:05","modified_gmt":"2026-07-07T10:42:05","slug":"age-related-eye-disease-study-areds","status":"publish","type":"post","link":"https:\/\/www.eyecliniclondon.com\/blog\/age-related-eye-disease-study-areds\/","title":{"rendered":"The Age-Related Eye Disease Study (AREDS): A Landmark Study in Macular Degeneration"},"content":{"rendered":"

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in older adults. If you develop AMD, the condition affects your macula\u2014the central part of the retina responsible for sharp, detailed vision\u2014making activities such as reading, driving, and recognising faces increasingly difficult as the disease progresses. Although AMD does not usually cause complete blindness, it can have a significant impact on your independence and quality of life.<\/p>\n

One of the most influential research projects in ophthalmology is the Age-Related Eye Disease Study (AREDS). Conducted by the National Eye Institute, this landmark clinical trial investigated whether a specific combination of nutritional supplements could slow the progression of age-related macular degeneration in people at risk of developing more advanced disease.<\/p>\n

The study significantly influenced the management of intermediate AMD and the care of people with late AMD in one eye. Researchers found that a carefully formulated combination of vitamins and minerals could significantly reduce the risk of progression to advanced AMD in certain patients, helping to reduce the risk of further disease progression in suitable patients However, these supplements are not recommended for everyone with AMD, and their benefits depend on the stage of the disease and your individual clinical circumstances.<\/p>\n

Today, the findings from the AREDS continue to influence international treatment guidelines and remain an important part of AMD management. Alongside regular eye examinations, healthy lifestyle choices, and appropriate monitoring, your ophthalmologist may recommend AREDS-based nutritional supplements if they are suitable for your condition, helping to reduce the risk of further vision loss over time.<\/p>\n

What Was the AREDS Study?<\/h2>\n

The Age-Related Eye Disease Study (AREDS) was a large, multicentre clinical trial designed to investigate whether specific nutritional supplements could influence the progression of age-related macular degeneration (AMD). If you have AMD or are at risk of developing advanced disease, the findings from this landmark study continue to play an important role in guiding your care.<\/p>\n

Researchers also examined whether the same combination of vitamins and minerals could reduce the development or progression of cataracts. Thousands of participants underwent comprehensive eye examinations and were followed over several years, allowing researchers to evaluate the long-term effects of nutritional supplementation on common age-related eye conditions.<\/p>\n

The AREDS became one of the most important nutrition-based clinical trials in ophthalmology. Its findings demonstrated that a specific formulation of antioxidant vitamins and minerals can reduce the risk of progression to advanced AMD in certain patients, helping ophthalmologists make evidence-based recommendations to preserve long-term vision.<\/p>\n

Why Was the Study Conducted?<\/h2>\n

Before the Age-Related Eye Disease Study (AREDS), researchers believed that oxidative stress might play an important role in damaging the retina and contributing to the development and progression of age-related macular degeneration (AMD). However, there was limited clinical evidence to show whether nutritional supplements could help protect the eye or slow the disease.<\/p>\n

Researchers wanted to determine whether a specific combination of antioxidant vitamins and minerals could protect retinal cells, reduce the risk of progression to advanced AMD, and help preserve vision. They also investigated whether these supplements had any effect on the development of cataracts. Reliable scientific evidence was needed before such supplements could be recommended as part of routine patient care.<\/p>\n

The AREDS was designed to answer these important clinical questions through a large, carefully conducted clinical trial. Its findings provided the evidence that now helps your ophthalmologist decide whether AREDS-based nutritional supplements may be appropriate for you, depending on the stage of your AMD and your individual risk of disease progression.<\/p>\n

Study Design<\/h2>\n

The Age-Related Eye Disease Study (AREDS) was a large, multicentre, randomised, controlled clinical trial involving participants with different stages of age-related macular degeneration (AMD). If you had AMD and met the study’s eligibility criteria, you could have been enrolled to help researchers determine whether nutritional supplements could influence the course of the disease.<\/p>\n

Participants were randomly assigned to receive either the AREDS nutritional supplement formulation, a placebo, or other treatment combinations according to the study design. Researchers then monitored each participant’s eye health over many years through regular eye examinations, assessing changes in the retina, visual acuity, and the progression of AMD.<\/p>\n

This rigorous study design produced highly reliable scientific evidence by allowing direct comparisons between the different treatment groups. The results have since formed the basis of modern recommendations for AREDS nutritional supplements, helping your ophthalmologist decide whether these supplements may reduce your risk of progressing to advanced AMD.<\/p>\n

Personalised Patient Care<\/h2>\n

\"\"<\/p>\n

Every person with age-related macular degeneration (AMD) has a different level of risk and disease severity. If you are diagnosed with AMD, your treatment and monitoring plan will be tailored to your individual needs rather than following a one-size-fits-all approach.<\/p>\n

Today, your ophthalmologist combines the findings from your clinical examination with retinal imaging, your family history, lifestyle factors, and the stage of your AMD when developing a personalised management plan. These factors help determine whether you may benefit from AREDS2 supplements, how frequently you should be monitored, and whether additional treatments are required.<\/p>\n

This personalised approach supports risk-based monitoring and more appropriate treatment decisions by ensuring that you receive care that matches your level of risk. Treatment decisions are therefore highly individualised, helping your ophthalmologist protect your vision while providing the most appropriate monitoring and management throughout the course of your condition.<\/p>\n

Who Took Part?<\/h2>\n

The Age-Related Eye Disease Study (AREDS) included thousands of adults aged between 55 and 80 years who had varying stages of age-related macular degeneration (AMD). If you have AMD, you may find the study particularly relevant because it involved people with different levels of disease severity, allowing researchers to understand how supplements affected a wide range of patients.<\/p>\n

Before entering the study, participants underwent comprehensive eye examinations to determine the stage of their AMD and assess their overall eye health. Throughout the trial, researchers carefully monitored retinal changes and visual acuity over several years. These regular assessments helped determine how the disease progressed and whether the nutritional supplements benefited participants with different stages of AMD<\/p>\n

The study’s long-term follow-up was one of its greatest strengths. By observing participants over many years, researchers gathered robust evidence about the effectiveness of the supplements. If you are diagnosed with intermediate or advanced AMD, you may benefit from recommendations based on these findings. Today, your ophthalmologist can use the AREDS evidence to decide whether these nutritional supplements are appropriate for you and your individual level of risk.<\/p>\n

The AREDS Supplement Formula<\/h2>\n

The original AREDS supplement formula combined high doses of vitamin C, vitamin E, beta-carotene, zinc, and copper. If you have intermediate or advanced age-related macular degeneration (AMD), your ophthalmologist may discuss whether an AREDS-based supplement is appropriate for you as part of your overall management plan.<\/p>\n

These nutrients were selected because of their antioxidant properties and their potential role in protecting retinal tissue from oxidative damage. Researchers wanted to determine whether this specific combination could help slow the progression of AMD and reduce the risk of developing advanced disease. Throughout the study, they carefully monitored participants to evaluate how well the supplement performed over time and whether it could benefit people like you who were at higher risk of vision loss.<\/p>\n

The findings showed that the AREDS formula could reduce the risk of progression to advanced AMD in certain patients, making it one of the most important nutritional interventions in ophthalmology. Today, your eye specialist can advise whether this formulation, or the updated AREDS2 version, is suitable for you based on the stage of your AMD, your medical history, and your individual risk factors.<\/p>\n

Key Findings<\/h2>\n

The Age-Related Eye Disease Study (AREDS) demonstrated that the nutritional supplement significantly reduced the risk of progression to advanced age-related macular degeneration (AMD) in people with intermediate AMD or advanced AMD in one eye. If you fall into one of these groups, your ophthalmologist may recommend an AREDS-based supplement to help lower your risk of developing more severe disease.<\/p>\n

The study also showed that the supplements did not cure AMD or restore vision that had already been lost. Instead, they helped reduce the likelihood of further retinal damage and slowed the progression of the condition. This means that if you have the appropriate stage of AMD, taking the recommended supplement may help preserve your remaining vision, but it is not a replacement for regular eye examinations or other treatments when needed.<\/p>\n

These findings represented a major breakthrough in AMD management and remain the foundation of current nutritional recommendations. Today, your ophthalmologist can assess the stage of your AMD and advise whether the AREDS or AREDS2 formulation is suitable for you as part of a personalised long-term care plan.<\/p>\n

Evidence Note: What Did AREDS Actually Find?<\/strong><\/p>\n

The original AREDS programme enrolled 4,757 participants aged 55 to 80 years, with the main AMD treatment analysis focusing on 3,640 participants who had AMD of varying severity.<\/p>\n

Among people at sufficiently high risk of progression, the combination of antioxidant vitamins and zinc reduced the five-year risk of developing advanced AMD by approximately 25%. It also reduced the risk of moderate visual-acuity loss, defined as losing 15 or more letters on a standard eye chart, by approximately 19%.<\/p>\n

For you as a patient, this means the formulation can provide meaningful protection if you have the stage of AMD shown to benefit. However, it does not cure AMD, restore vision already lost or guarantee that advanced AMD will never develop.<\/p>\n

What Did AREDS Find About Cataracts?<\/strong><\/p>\n

AREDS also investigated whether high-dose antioxidant supplementation could slow the development or progression of age-related cataracts. The cataract trial did not find a statistically significant benefit of the antioxidant formulation on the development or progression of age-related lens opacities.<\/p>\n

For patients, this is an important distinction. AREDS and AREDS2 supplements are used for selected people at risk of AMD progression; they should not be presented as proven treatments for preventing cataracts.<\/p>\n

UK Clinical Practice Note<\/h3>\n

UK practice broadly reflects the principle that AREDS-based supplementation is aimed at selected people with a meaningful risk of AMD progression rather than everyone with early retinal changes.<\/p>\n

The Royal College of Ophthalmologists’ 2024 AMD commissioning guidance states that the original AREDS formulation reduced the five-year risk of late AMD by an estimated 25% in at-risk individuals, including people with bilateral large drusen or large drusen in one eye and late AMD in the fellow eye. It also notes the AREDS2 development towards lutein and zeaxanthin in place of beta-carotene for former smokers.<\/p>\n

The guidance recommends a healthy diet rich in fresh fruit, vegetables, eggs and oily fish. It also notes that licensed multivitamin products containing the AREDS2 formulation are not available on NHS prescription, although patients may choose to obtain appropriate products over the counter.<\/p>\n

For you, this means supplement decisions should be based on the stage and features of your AMD rather than simply buying a product labelled as an \u201ceye vitamin\u201d.<\/p>\n

Lifestyle Still Matters<\/h2>\n

The findings from the Age-Related Eye Disease Study (AREDS) highlighted that nutritional supplements should complement healthy lifestyle choices rather than replace them. If you have age-related macular degeneration (AMD), taking an AREDS or AREDS2 supplement is only one part of protecting your long-term vision.<\/p>\n

Healthy lifestyle habits continue to play an important role in supporting eye health. Stopping smoking, eating a balanced diet rich in leafy green vegetables and oily fish, exercising regularly, maintaining a healthy weight, and protecting your eyes from excessive ultraviolet (UV) exposure may all contribute to better overall eye health and help reduce the risk of further retinal damage.<\/p>\n

By combining healthy lifestyle choices with regular eye examinations and any recommended treatments or supplements, you can take a proactive approach to managing AMD. Your ophthalmologist can advise you on the most appropriate combination of lifestyle measures and medical care based on your individual needs and stage of the condition.<\/p>\n

Who Benefits from AREDS Supplements?<\/h2>\n

AREDS supplements are not suitable for everyone with age-related macular degeneration. Whether they may help depends mainly on the stage of AMD and the risk of further progression. Your ophthalmologist will assess your retinal health before recommending an AREDS or AREDS2 supplement.<\/p>\n